Retatrutide represents the new frontier of metabolic peptides. Where Semaglutide targets a single receptor (GLP-1) and Tirzepatide targets two (GLP-1 + GIP), Retatrutide simultaneously activates three key hormonal receptors — GLP-1, GIP, and GCG — making it the most comprehensive agonist in its class to date.
Studied Mechanism of Action
The combined activation of the three receptors acts synergistically on:
GLP-1 — appetite and blood sugar regulation
GIP — insulin sensitivity and lipid metabolism
GCG — energy reserve mobilization and caloric expenditure
Research Areas
Weight loss related to obesity (up to 24% body weight reduction)
